Trials / Recruiting
RecruitingNCT07136012
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 11,000 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 50 Years – 105 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olpasiran | Olpasiran will be administered via SC injection. |
| DRUG | Placebo | Placebo will be administered via SC injection. |
Timeline
- Start date
- 2025-08-22
- Primary completion
- 2031-10-20
- Completion
- 2031-10-20
- First posted
- 2025-08-22
- Last updated
- 2026-04-16
Locations
241 sites across 3 countries: United States, Australia, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07136012. Inclusion in this directory is not an endorsement.